Breast Cancer in Older Patients

Seminars in Oncology

Volumn 31, Issue 2, 2004, Pages 234-248

  Kimmick, Gretchen ^a   Muss, Hyman B ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ESTROGEN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PAMIDRONIC ACID; TAMOXIFEN; TRASTUZUMAB;

AGED; ANEMIA; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARDIOTOXICITY; COMORBIDITY; FRACTURE; FRAGILITY FRACTURE; GERIATRIC CARE; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; HYPERCALCEMIA; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT PLANNING; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 1842631405     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.033     Document Type: Article

References (133)

1. Jemal A, Murray T, Samuels A, et al: Cancer Statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Adami HO, Malker B, Holmberg L, et al: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559-563, 1986
3. Holli K, Isola J: Effect of age on the survival of breast cancer patients. Eur J Cancer 33:425-428, 1997
4. Host H, Lund E: Age as a prognostic factor in breast cancer. Cancer 57:2217-2221, 1986
5. Bergman L, Kluck HM, van Leeuwen FE, et al: The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: A population-based study. Eur J Cancer 28A:1475-1480, 1992
6. Yancik R, Ries LG, Yates JW: Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 63:976-981, 1989
7. Herbsman H, Feldman J, Seldera J, et al: Survival following breast cancer surgery in the elderly. Cancer 47:2358-2363, 1981
8. Lyman GH, Lyman S, Balducci L, et al: Age and the risk of breast cancer recurrence. Cancer Control 3:421-427, 1996
9. Masetti R, Antinori A, Terribile D, et al: Breast cancer in women 70 years of age or older. J Clin Oncol 13:2722-2730, 1996
10. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000
11. Yancik R, Wesley MN, Ries LAG, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001
12. Golledge J, Wiggins JE, Callam MJ: Age-related variation in the treatment and outcomes of patients with breast carcinoma. Cancer 88:369-374, 2000
13. Goodwin JS, Samet JM, Key CR, et al: Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc 34:20-26, 1986
14. Satariano WA, Belle SH, Swanson GM: The severity of breast cancer at diagnosis: A comparison of age and extent of disease in black and white women. Am J Public Health 76:779-782, 1986
15. Holmes FF, Hearne E: Cancer stage-to-age relationship: Implications for cancer screening in the elderly. J Am Geriatr Soc 29:55-57, 1981
16. American Geriatrics Society Clinical Practice Committee: AGS Position Statement: Breast cancer screening in older women. J Am Geriatr Soc 48:842-844, 2000
17. Greenfield S, Blanco DM, Elashoff RM, et al: Patterns of care related to age of breast cancer patients. JAMA 257:2766-2770, 1987
18. Silliman RA, Guadagnoli E, Weitberg AB, et al: Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 44:M46-M50, 1989
19. Mohle-Boetani J: Age at breast cancer diagnosis as a predictor of subsequent survival, in Macieira-Coehlo A, Nordenskjold B (eds): Cancer and Aging. Boca Raton, FL, CRC Press, 1990, pp 245-254
20. Lazovich DA, White E, Thomas DB, et al: Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA 266:3433-3438, 1991
21. Repetto L, Costantini M, Campora E, et al: A retrospective comparison of detection and treatment of breast cancer in young and elderly patients. Breast Cancer Res Treat 43:27-31, 1997
22. Silliman RA, Balducci L, Goodwin JS, et al: Breast cancer care in old age: What we know, don't know, and do. J Natl Cancer Inst 85:190-199, 1993
23. Newschaffer CJ, Penberthy L, Desch CE, et al: The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 156:85-90, 1996
24. Velanovich V, Gabel M, Walker EM, et al: Causes for the undertreatment of elderly breast cancer patients: Tailoring treatments to individual patients. J Am Coll Surg 194:8-13, 2002
25. Bickell NA, McEvoy MD: Physicians' reasons for failing to deliver effective breast cancer care. A framework for underuse. Med Care 41:442-446, 2003
26. Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 48:974-979, 1981
27. Meyer JS, Hixon B: Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res 39:4042-4047, 1979
28. Taylor IW, Musgrove EA, Friedlander ML, et al: The influence of age on the DNA ploidy levels of breast-tumors. Eur J Cancer Clin Oncol 19:623-628, 1983
29. McCarty KS, Silva JS, Cox EB, et al: Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg 197:123-127, 1983
30. von Rosen A, Gardelin A, Auer G: Assessment of malignancy potential in mammary carcinoma in elderly patients. Am J Clin Oncol 10:61-64, 1987
31. Honma N, Sakamoto G, Akiyama F, et al: Breast carcinoma in women over the age of 85: Distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 42:120-127, 2003
32. Toikkanen S, Kujari H: Pure and mixed mucinous carcinomas of the breast: A clinicopathologic analysis of 61 cases with long-term follow-up. Hum Pathol 20:758-764, 1989
33. Vicini FA, Recht A: Age at diagnosis and outcome for women with ductal carcinoma-in-situ: A critical review of the literature. J Clin Oncol 20:2736-2744, 2002
34. Rodrigues NA, Dillon D, Carter D, et al: Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97:1393-1403, 2003
35. US Department of Health and Human Services: Health United States 1996-7 and Injury Chartbook. 1997. Washington, DC, DHHS Publication No. (PHS) 97-1232
36. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994
37. Fish EB, Chapman JA, Link MA: Competing causes of death for primary breast cancer. Ann Surg Oncol 5:368-375, 1998
38. Wolinsky FD, Johnson RL, Stump TE: The risk of mortality among older adults over an eight-year period. Gerontologist 35:150-161, 1995
39. Ferrucci L, Guralnik JM, Cecchi F, et al: Constant hierarchic patterns of physical functioning across seven populations in five countries. Gerontologist 38:286-294, 1998
40. Bernard SL, Kincade JE, Konrad TR, et al: Predicting mortality from community surveys of older adults: The importance of self-rated functional ability. Psychol Sci Soc Sci 52: S155-S166, 1997
41. Dunlop DD, Hughes SL, Mannheim LM: Disability patterns in activities of daily living: Patterns of change and a hierarchy of disability. Am J Public Health 87:378-383, 1997
42. Greiner PA, Snowdon DA, Greiner LH: The relationship of self-rated function and self-rated health to concurrent functional ability, functional decline and mortality: Findings from the Nun Study. Psychol Sci Soc Sci 51:S234-S241, 1996
43. Satariano WA, Ragheb NE, Dupuis MA: Comorbidity in older women with breast cancer: An epidemiologic approach, in Yancik R, Yates J (eds): Cancer in the Elderly: Approaches to Early Detection and Treatment. New York, NY, Springer, 1989, pp 71-107
44. Satariano WA: Comorbidity and functional status in older women with breast cancer: Implications for screening, treatment, and prognosis. J Gerontol 47:24-31, 1992
45. Satariano WA: Aging, comorbidity, and breast cancer survival: An epidemiologic view. Adv Exp Med Biol 330:1-11, 1993
46. Vaeth PA, Satariano WA, Ragland DR: Limiting comorbid conditions and breast cancer stage at diagnosis. J Gerontol A Biol Sci Med Sci 55:M593-M600, 2000
47. Goodwin JS, Hunt WC, Samet JM: Determinants of cancer therapy in elderly patients. Cancer 72:594-601, 1993
48. Turnbull AD, Gundy E, Howland WS, et al: Surgical mortality among the elderly. An analysis of 4,050 operations (1970-1974). Clin Bull 8:139-142, 1978
49. Singletary SE, Shallenberger R, Guinee VF: Breast cancer in the elderly. Ann Surg 218:667-671, 1993
50. Margolese RG, Foster RS Jr: Tamoxifen as an alternative to surgical resection for selected geriatric patients with primary breast cancer. Arch Surg 124:548-550, 1989
51. Bradbeer JW, Kyngdon J: Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol 9:31-34, 1983
52. Allan SG, Rodger A, Smyth JF, et al: Tamoxifen as primary treatment of breast cancer in elderly or frail patients: A practical management. BMJ 290:358, 1985
53. Akhtar SS, Allan SG, Rodger A, et al: A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol 17:30-35, 1991
54. Ciatto S, Bartoli D, Iossa A, et al: Response of primary breast cancer to tamoxifen alone in elderly women. Tumori 77:328-330, 1991
55. Ciatto S, Cirillo A, Confortini M, et al: Tamoxifen as primary treatment of breast cancer in elderly patients. Neoplasma 43:43-45, 1996
56. Bergman L, van Dongen JA, van Ooijen B, et al: Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat 34:77-83, 1995
57. Horobin JM, Preece PE, Dewar JA, et al: Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78:213-217, 1991
58. Preece PE, Wood RA, Mackie CR, et al: Tamoxifen as initial sole treatment of localized breast cancer in elderly women: A pilot study. BMJ 284:869-870, 1982
59. Gaskell DJ, Hawkins RA, de Carteret S, et al: Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg 79:1317-1320, 1992
60. VanDalsen AD, DeVries JE: Treatment of breast cancer in elderly patients. J Surg Oncol 60:80-82, 1995
61. Robertson JF, Todd JH, Ellis IO, et al: Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ 297:511-514, 1988
62. Gazet JC, Markopoulos C, Ford HT, et al: Prospective randomized trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet 1:679-681, 1988
63. Gazet JC, Ford HT, Coombes RC, et al: Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20:207-214, 1994
64. Bates T, Riley DL, Houghton J, et al: Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 78:591-594, 1991
65. Mustacchi G, Milani S, Pluchinotta A, et al: Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 14:2197-2200, 1994
66. Mustacchi G, Ceccherini R, Milani S, et al: Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14:414-420, 2003
67. Maher M, Campana F, Mosseri V, et al: Breast cancer in elderly women: A retrospective analysis of combined treatment with tamoxifen and once-weekly irradiation. Int J Radiat Oncol Biol Phys 31:783-789, 1995
68. Clark RM, McCulloch PB, Levine MN, et al: Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84:683-689, 1992
69. Kantorowitz DA, Poulter CA, Sischy B, et al: Treatment of breast cancer among elderly women with segmental mastectomy or segmental mastectomy plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 15:263-270, 1988
70. Reed MW, Morrison JM: Wide local excision as the sole primary treatment in elderly patients with carcinoma of the breast. Br J Surg 76:898-900, 1989
71. Veronesi U, Luini A, Del Vecchio M, et al: Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 328:1587-1591, 1993
72. Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-681, 1985
73. Fisher B, Jeong JH, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002
74. Cabanes PA, Salmon RJ, Vilcoq JR, et al: Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 339:1245-1248, 1992
75. Mandelblatt JS, Edge SB, Meropol NJ, et al: Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast cancer. Cancer 95:2445-2454, 2002
76. Mandelblatt JS, Edge SB, Meropol NJ, et al: Predictors of long-term outcomes in older breast cancer survivors: Perceptions versus patterns of care. J Clin Oncol 21:855-863, 2003
77. McMasters KM, Tuttle TM, Carlson DJ, et al: Sentinel lymph node biopsy for breast cancer: A suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560-2566, 2000
78. Giuliano AE, Haigh PI, Brennan MB, et al: Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 18:2553-2559, 2000
79. Martelli G, Moglia D, Boracchi P, et al: Surgical resection plus tamoxifen as treatment of breast cancer in elderly patients: A retrospective study. Eur J Cancer 29A:2080-2082, 1993
80. Martelli G, DePalo G, Rossi N, et al: Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen. Br J Cancer 72:1251-1255, 1995
81. Martelli G, Miceli R, De Palo G, et al: Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? Cancer 97:1156-1163, 2003
82. Deutsch M: Radiotherpay after lumpectomy for breast cancer in very old women. Am J Clin Oncol 25:48-49, 2002
83. Cooke AL, Perera F, Fisher B, et al: Tamoxifen with and without radiation after partial mastectomy in patients with involved nodes. Int J Radiat Oncol Biol Phys 31:777-781, 1995
84. Fyles A, McCready D, Manchul L, et al: Preliminary results of a randomized study of tamoxifen +/- breast radiation in T1/2 NO disease in women over 50 years of age. Proc Am Soc Clin Oncol 20:24a, 2001 (abstr)
85. Hughes KS, Schnaper L, Berry D, et al: Comparison of lumpectomy plus tamoxifen with and without radiotherpay in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) breast carcinoma. Proc Am Soc Clin Oncol 20:24a, 2001 (abstr)
86. Rostom AY, Pradhan DG, White WF: Once weekly irradiation in breast cancer. Int J Radiat Oncol Biol Phys 13:551-555, 1987
87. Kimmick GG, Muss HB: Systemic therapy for older women with breast cancer. Oncology NY 15:280-291, 2001
88. Extermann M, Balducci L, Lyman GH: What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 18:1709-1717, 2000
89. Loprinzi CL, Thome SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19:972-979, 2001
90. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
91. Anonymous: Tamoxifen for early breast cancer: An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
92. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
93. Early Breast Cancer Trialists' Collaborative Group: Anonymous: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
94. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
95. Aapro MS: Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St Gallen, February 2001. Oncologist 6:376-385, 2001
96. Du X, Goodwin JS: Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer 92:730-737, 2001
97. Colleoni M, Price KN, Castiglione-Gertsch M, et al: Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Lancet 354:130-131, 1999
98. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Groups Trial VII. J Clin Oncol 18:1412-1422, 2000
99. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
100. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
101. Wils JA, Bliss JM, Marty M, et al: Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 17:1988-1998, 1999
102. Ellis MJ, Hayes DF, Lippman ME: Treatment of metastatic breast cancer, in Harris JR, Lippman ME, Morrow M (eds): Diseases of the Breast. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 749-797
103. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
104. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 19:2596-2606, 2001
105. Jones S, Vogel C, Arkhipov A, et al: Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17:3418-3425, 1999
106. Kaufmann M, Bajetta E, Dirix LY, et al: Exemestane improves survival compared with megoestrol acetate in post-menopausal patients with advanced breast cancer who have failed on tamoxifen: Results of a double-blind randomised phase III trial. Eur J Cancer 36:S86-S87, 2000
107. Osborne CK, Pippen J, Jones SE, et al: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20:3386-3395, 2002
108. Carlson RW: Sequencing of endocrine therapies in breast cancer-Integration of recent data. Breast Cancer Res Treat 75:S27-S32, 2002
109. Taylor SG, Gelman RS, Falkson G, et al: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104:455-461, 1986
110. Anonymous: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 4:186-193, 1986
111. Begg CB, Elson PJ, Carbone PP: A study of excess hematologic toxicity in elderly patients treated on chemotherapy protocols, in Yancik R (ed): Cancer in the Elderly: Approaches to Early Detection and Management. New York, NY, Springer-Verlag, 1989, pp 149-161
112. Gelman RS, Taylor SG: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984
113. Christman K, Muss HB, Case LD, et al: Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA 268:57-62, 1992
114. Ibrahim NK, Frye DK, Buzdar AU, et al: Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 156:882-888, 1996
115. Giovanazzi-Bannon S, Rademaker A, Lai G, et al: Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study. J Clin Oncol 12:2447-2452, 1994
116. Ibrahim NK, Hortobagyi GN, Ewer M, et al: Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: The M.D. Anderson experience. Cancer Chemother Pharmacol 43:471-478, 1999
117. Du XL, Oxborne C, Goodwin JS: Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642, 2002
118. Ravdin PM, Valero V: Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol 22:17-21, 1995 (suppl 4)
119. Hortobagyi GN, Holmes FA: Single-agent paclitaxel for the treatment of breast cancer: An overview. Semin Oncol 23:4-9, 1996 (suppl 1)
120. Perez EA, Vogel CL, Irwin DH, et al: Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73:85-88, 2002
121. Sorio R, Robieux I, Galligioni E, et al: Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 33:301-303, 1997
122. Vogel C, O'Rourke M, Winer E, et al: Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10:397-402, 1999
123. Ranson MR, Carmichael J, O'Byrne K, et al: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997
124. Blum JL, Buzdar AU, LoRusso PM, et al: A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 17:125a, 1998 (abstr)
125. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
126. Cobleigh MA, Vogel CL, Tripathy D, et al: Efficacy and safety of HerceptinTM (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherpay for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr)
127. Vogel C, Cobleigh M, Tripathy D, et al: First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 19:71a, 2000 (abstr)
128. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
129. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
130. Hillner BE, Ingle JN, Berenson JR, et al: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18:1378-1391, 2000
131. Del Mastro L, Venturini M, Lionetto R, et al: Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15:2715-2721, 1997
132. Trimble EL, Carter CL, Cain D, et al: Representation of older patients in cancer treatment trials. Cancer 74:2208-2214, 1994
133. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999